BREXIT consequences - relocation of the European Medicines Agency

Abstract

Introduction The UK decision to leave the European Union (BREXIT) has many potential consequences for the health of European citizens. One of the actions already taken has been the decision to move the location of the European Medicines Agency (EMA) from Canary Wharf in London to Amsterdam from April 2019. Aim The aim of this article is to analyze the EU criteria for the process of EMA relocation from London to Amsterdam based on the comparison of the EMA bids placed by the EU candidates and the indicators among those member states (MSs). Materials and Methods Documentary and analytical methods are used to provide scientific data on the decision of EMA relocation from London to Amsterdam and the consequences of BREXIT from a drug policy point of view. Many different indicators, like accommodation, living cost were compared and surveyed in the MSs. Results EU opened procedure for EMA relocation after BREXIT in 2017. A total of 19 cities have applied to host the EMA headquarters, including Bulgaria, with Amsterdam winning the battle. EMA is working with the Dutch authorities and the relocation of EMA to Amsterdam is a fact. Bulgaria, Hungary, and Croatia were the top three countries with the lowest possible living costs, and accommodation. Conclusion After EMA relocation to Amsterdam as a result of BREXIT, the pharmaceutical industry is dealing with significant implications in order not to lose its market access. Many innovative and generic medicines across the MSs updated their marketing authorizations due to the fact that the exclusion of the UK from all medicines authorization procedures should be finalised by the end of March 2019.